For our final liveblog day we’re back at the Informa Biotech Showcase for more packed panels on AI and funding, a panel on ...

Continued pricing pressures from governments and patient groups are driving small molecule CDMOs to focus on reducing the ...

The action affects the TROPOS trial of cibotacept (KER-012), an activin signalling inhibitor that works in a similar way to ...

In today’s pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Isaac Bentwich, CEO and founder of Quris.AI, about ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...

With the expiry of multiple biologic patents fast approaching, there is a huge opportunity for the NHS to make further ...

TED is a rare autoimmune disorder in which the muscles and fatty tissues behind the eye become inflamed, causing the eyes to ...

The success of strategies focused on development, change management partnerships, progression flexibility, recognition ...

That is the conclusion of a report by the global Commission on Clinical Obesity – published in The Lancet Diabetes and ...

To date, Leqembi has been approved in the US, Japan, China, South Korea, Hong Kong, Israel, UAE, GB, Mexico, and Macau, and ...

Pharmacy numbers dropped from 11,522 in 2022 to 11,414 in 2023, and a further 436 closed this year in 2024. As numbers ...